XY Capital’s Novo Nordisk NVO Stock Holding History

XY Capital’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-4,308	Closed	-$343K	–	133
2023 Q1	$343K	Buy	+4,308	New	+$305K	0.13%	84

Other funds holding NVO

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

XY Capital's NVO Position: Q2 2023 in Review

XY Capital sold out of Novo Nordisk (NVO) in Q2 2023, closing a stake of 4,308 shares — an estimated $343K sold.

XY Capital first reported a position in NVO in Q1 2023 and held it in 1 quarter. The position peaked at $343K in Q1 2023. 1,197 funds tracked by Wall St. Rank hold NVO as of Q2 2023.

XY Capital reported no remaining Novo Nordisk position as of Q2 2023 after selling out during the quarter.
XY Capital sold 4,308 Novo Nordisk shares in Q2 2023, an estimated $343K.
XY Capital first reported a position in Novo Nordisk in Q1 2023 and held it in 1 quarter.
XY Capital's Novo Nordisk position peaked at $343K in Q1 2023.
1,197 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2023.

Based on XY Capital's 13F filing for Q2 2023, filed 28 Jul 2023.